Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01863199 · ClinicalTrials.gov registry record · Phase 4
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
A Phase 4 study of Neovascular Age-related Macular Degeneration, sponsored by Retinal Consultants of Arizona.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT01863199: Completed Phase 4 study of Neovascular Age-related Macular Degeneration, sponsored by Retinal Consultants of Arizona.
NCT01863199 is a Phase 4 study of Neovascular Age-related Macular Degeneration that has completed, run by Retinal Consultants of Arizona. The registered enrollment target is 60 participants, below the 407-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01863199, a Phase 4 study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Retinal Consultants of Arizona.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
A study to use in home technology to reduce the burden of in office visits and injections.
Primary Outcome
Best corrected visual acuity (BCVA), as assessed by the number of letters read correctly on the Early Treatment Diabetic Retinoptahy Study (ETDRS) eye chart at a starting test distance of 4 meters, at Months 3, 6, 9 and 12
Conditions Studied
Interventions
- DRUG Lucentis (Treat and extend)
- DRUG Lucentis every 4 weeks
- DRUG Lucentis every 12 weeks
Study Locations (4)
Arizona
- Retinal Consultants of Arizona - Gilbert
- Retinal Consultants of Arizona - Mesa
- Retinal Consultants of Arizona - Peoria
- Retinal Consultants of Arizona - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-12 |
| Phase | Phase 4 |
What the finished NCT01863199 record still lists
NCT01863199 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 407-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which Lucentis (Treat and extend) is the first listed.
NCT01863199 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT01863199 about?
NCT01863199 is a clinical study titled "Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)". A study to use in home technology to reduce the burden of in office visits and injections.
What is the current status of trial NCT01863199?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2013-05. Estimated completion is 2015-12.
What conditions does trial NCT01863199 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT01863199?
The interventions under investigation include: Lucentis (Treat and extend) (DRUG), Lucentis every 4 weeks (DRUG), Lucentis every 12 weeks (DRUG).
Who is sponsoring clinical trial NCT01863199?
This trial is sponsored by Retinal Consultants of Arizona, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01863199 being conducted?
This trial has 4 study locations across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01863199's enrollment target sits among peer trials
60 20th of 33 higher than 13 of 33 other Neovascular Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
RECRUITING · Phase 4
-
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 3
-
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
-
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
RECRUITING · Phase 3
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia